Marasini B, Vyas H, Lakhashe S, Hariraju D, Akhtar A, Ratcliffe S
AIDS. 2021; 35(15):2423-2432.
PMID: 34402452
PMC: 8631165.
DOI: 10.1097/QAD.0000000000003050.
Guan Q, Warrington R, Moreno S, Qing G, Weiss C, Peng Z
Future Sci OA. 2019; 5(7):FSO405.
PMID: 31428451
PMC: 6695525.
DOI: 10.2144/fsoa-2018-0125.
Sahni A, Nagendra A, Menon P
Med J Armed Forces India. 2016; 58(1):66-9.
PMID: 27365663
PMC: 4923951.
DOI: 10.1016/S0377-1237(02)80017-X.
Shmelkov E, Nadas A, Cardozo T
Hum Vaccin Immunother. 2014; 10(10):3013-6.
PMID: 25483466
PMC: 5443089.
DOI: 10.4161/21645515.2014.972148.
Davis D, Koornstra W, Fagrouch Z, Verschoor E, Heeney J, Bogers W
PLoS One. 2013; 8(8):e72702.
PMID: 23977339
PMC: 3745472.
DOI: 10.1371/journal.pone.0072702.
The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.
Farquhar C, John-Stewart G
Clin Exp Immunol. 2003; 134(3):367-77.
PMID: 14632739
PMC: 1808883.
DOI: 10.1111/j.1365-2249.2003.02292.x.
Probing hydrogen bonds in the antibody-bound HIV-1 gp120 V3 loop by solid state NMR REDOR measurements.
Balbach J, Yang J, Weliky D, Steinbach P, Tugarinov V, Anglister J
J Biomol NMR. 2000; 16(4):313-27.
PMID: 10826883
DOI: 10.1023/a:1008343623240.
Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.
Spenlehauer C, Saragosti S, Fleury H, KIRN A, Aubertin A, Moog C
J Virol. 1998; 72(12):9855-64.
PMID: 9811721
PMC: 110497.
DOI: 10.1128/JVI.72.12.9855-9864.1998.
An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.
Stamatatos L, Cheng-Mayer C
J Virol. 1998; 72(10):7840-5.
PMID: 9733820
PMC: 110102.
DOI: 10.1128/JVI.72.10.7840-7845.1998.
The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.
Schreiber M, Wachsmuth C, Muller H, Odemuyiwa S, Schmitz H, Meyer S
J Virol. 1997; 71(12):9198-205.
PMID: 9371578
PMC: 230222.
DOI: 10.1128/JVI.71.12.9198-9205.1997.
Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode.
Nakano I, Maertens G, Major M, Vitvitski L, Dubuisson J, Fournillier A
J Virol. 1997; 71(9):7101-9.
PMID: 9261444
PMC: 192006.
DOI: 10.1128/JVI.71.9.7101-7109.1997.
Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.
Montefiori D
Springer Semin Immunopathol. 1997; 18(3):371-90.
PMID: 9089955
DOI: 10.1007/BF00813504.
Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.
Fouts T, Binley J, Trkola A, Robinson J, Moore J
J Virol. 1997; 71(4):2779-85.
PMID: 9060632
PMC: 191401.
DOI: 10.1128/JVI.71.4.2779-2785.1997.
Vanadium oxoanions and cAMP-dependent protein kinase: an anti-substrate inhibitor.
Pluskey S, Mahroof-Tahir M, Crans D, Lawrence D
Biochem J. 1997; 321 ( Pt 2):333-9.
PMID: 9020863
PMC: 1218073.
DOI: 10.1042/bj3210333.
Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis.
Janini L, Pieniazek D, Peralta J, Schechter M, Tanuri A, Vicente A
Virus Genes. 1996; 13(1):69-81.
PMID: 8938982
DOI: 10.1007/BF00576981.
A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages.
Handley M, Steigbigel R, Morrison S
J Virol. 1996; 70(7):4451-6.
PMID: 8676469
PMC: 190379.
DOI: 10.1128/JVI.70.7.4451-4456.1996.
Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.
Klasse P, Moore J
J Virol. 1996; 70(6):3668-77.
PMID: 8648701
PMC: 190242.
DOI: 10.1128/JVI.70.6.3668-3677.1996.
Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent....
Kostrikis L, Cao Y, Ngai H, Moore J, Ho D
J Virol. 1996; 70(1):445-58.
PMID: 8523557
PMC: 189833.
DOI: 10.1128/JVI.70.1.445-458.1996.
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
Roderiquez G, Oravecz T, BERMAN P, Lusso P, Norcross M
J Virol. 1994; 68(9):6006-13.
PMID: 8057475
PMC: 237005.
DOI: 10.1128/JVI.68.9.6006-6013.1994.
Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.
Hogervorst E, de Jong J, van Wijk A, Bakker M, Valk M, Nara P
J Virol. 1995; 69(10):6342-51.
PMID: 7666535
PMC: 189533.
DOI: 10.1128/JVI.69.10.6342-6351.1995.